Marinus Pharmaceuticals, Inc.
170 N Radnor Chester Road
Radnor
PA
19087
United States
Tel: 484-801-4674
Website: http://www.marinuspharma.com/
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to improving the lives of patients; women suffering from postpartum depression; children suffering from drug-resistant epilepsies such as CDKL5 deficiency disorder (a serious, rare genetic epilepsy), and rare behavior disorders, such as FXS (Fragile X Syndrome).
We are developing Ganaxolone in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is preparing to initiate a pivotal study in children with rare, CDKL5 deficiency disorder and currently conducting studies in postpartum depression and refractory status epilepticus.
Our team is determined to bring these drugs to the patients who need them; and improve their quality of life and the quality of life for their loved ones. We are seeking team members who want to be part of a dynamic and cohesive team ready use his/her talents to their full potential.
Stock Symbol: MRNS
Stock Exchange: Nasdaq
106 articles with Marinus Pharmaceuticals, Inc.
-
Shares of Marinus Pharmaceuticals soared more than 60% in after-hours trading Monday following the company’s announcement that its experimental epilepsy treatment ganaxolone hit the mark in a Phase III study.
-
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy
9/14/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced positive top-line results from its registrational Phase 3 clinical trial (Marigold Study) evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures.
-
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences - Sep 08, 2020
9/8/2020
Marinus Pharmaceuticals, Inc. announced that management will present at the Morgan Stanley Virtual Global Healthcare Conference, H.C Wainwright Virtual Global Investment Conference and Cantor Virtual Global Healthcare Conference during the week of September 14.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 12, 2020
8/12/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to seven new employees.
-
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
8/6/2020
Clinical trials remain on track, with Refractory Status Epilepticus (SE) trial expected to begin enrollment shortly CDKL5 deficiency disorder (CDD) pivotal topline results on track for Q3; Conference call to be scheduled to discuss CDD data release and business update Organization further strengthened with new additions to both the Board of Directors and management team RADNOR, Pa.--( BUSINESS WIRE )-- Marinus Pharmaceuticals
-
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)
7/30/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD) , a rare refractory form of pediatric epilepsy.
-
Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors
7/29/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Charles (“Chuck”) Austin to its Board of Directors.
-
Marinus Pharmaceuticals Provides Pipeline Update - June 30, 2020
6/30/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, provided a pipeline update in advance of it clinical and commercial overview webinar to be held Tuesday, June 30, 2020 from 8am – 10:30am Eastern Time.
-
Marinus Pharmaceuticals to Host Pipeline Update Webinar
6/24/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex. In addition, there will be four key opinion leaders participating in the event, which
-
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum
6/22/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Series: 2 nd Annual CNS Forum. Additional details can be found below: Title: A Pipeline Update with Scott Braunstein (CEO) and Joe Hulihan (CMO) Date: Tuesday, June 23, 2020 Time: 3:20 PM Easter
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 16, 2020
6/16/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of an inducement award to a new employee.
-
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary
6/15/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary. “We are thrilled to welcome Martha to our growing team at Marinus, and believe her legal experience supporting biopharma companies across all development stages will be instr
-
Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/2/2020
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18,400,000 shares of common stock at a public offering price of $2.50 per share, including the exercise in full by the underwriters of their option to purchase up to 2,400,000 additional shares of common stock.
-
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock
5/28/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering
-
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5/28/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $2.50 per share.
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
5/4/2020
Marinus Pharmaceuticals, Inc. today reported its financial results for the first quarter ended March 31, 2020.
-
Marinus Pharmaceuticals Announces Formation of Scientific Advisory BoardBoard includes 6 globally recognized seizure disorder experts
4/30/2020
Marinus Pharmaceuticals, Inc. announced the formation of a Scientific Advisory Board with the appointment of six leading experts in clinical neurology and seizure disorders: Jacqueline French, M.D., Lawrence Hirsch, M.D., Aatif Husain, M.D., Michael Rogawski M.D., Ph.D., Eugen Trinka, M.D. and Henrikas Vaitkevicius, M.D.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 27, 2020
4/27/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to two new employees.
-
Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020
4/23/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced that it will release financial results for the first quarter ended March 31, 2020 before the market open on Monday, May 4, 2020.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - March 23, 2020
3/23/2020
Marinus Pharmaceuticals, Inc. announced the grant of inducement awards to three new employees.